

KMT1 family methyltransferases regulate heterochromatin-nuclear periphery tethering via histone and non-histone protein methylation

Radhika Arasala Rao, Alhad Ashok Ketkar, Neelam Kedia, Vignesh K Krishnamoorthy, Vairavan Lakshmanan, Pankaj Kumar, Abhishek Mohanty, Shilpa Dilip Kumar, Sufi O Raja, Akash Gulyani, ChandraPrakash Chaturvedi, Marjorie Brand, Dasaradhi Palakodeti, Shravanti Rampalli

5		
Review timeline:	Submission date:	24 August 2016
	Editorial Decision:	28 September 2016
	Resubmission:	17 January 2018
	Editorial Decision:	26 February 2018
	Revision received:	27 March 2018
	Editorial Decision:	11 June 2018
	Revision received:	19 January 2019
	Editorial Decision:	31 January 2019
	Revision received:	7 February 2019
	Accepted:	12 February 2019

Editor: Esther Schnapp

Transaction Report:

No Peer Review Process File is available with this article, as the authors have chosen not to make the review process public.

EMBO PRESS

YOU MUST COMPLETE ALL CELLS WITH A PINK BACKGROUND $oldsymbol{\Psi}$

PLEASE NOTE THAT THIS CHECKLIST WILL BE PUBLISHED ALONGSIDE YOUR PAPER

Corresponding Author Name: Dr. Shravanti Rampalli Journal Submitted to: EMBO Reports Manuscript Number: EMBOR-2016-43260

Reporting Checklist For Life Sciences Articles (Rev. June 2017)

This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. These guidelines are consistent with the Principles and Guidelines for Reporting Preclinical Research issued by the NIH in 2014. Please follow the journal's authorship guidelines in preparing your manuscript.

A- Figures

1. Data

The data shown in figures should satisfy the following conditions:

- the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner.
- → figure panels include only data points, measurements or observations that can be compared to each other in a scientifically
- Inguire paries include only data points, measurements of observations that can be compared to each other in a scientifican meaningful way.
 graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates.
- if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be iustified
- → Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship

Each figure caption should contain the following information, for each panel where they are relevant:

- a specification of the experimental system investigated (eg cell line, species name).
- the assay(s) and method(s) used to carry out the reported observations and measurer
 an explicit mention of the biological and chemical entity(ies) that are being measured
- → an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
- → the exact sample size (n) for each experimental group/condition, given as a number, not a range;
- a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
 a statement of how many times the experiment shown was independently replicated in the laboratory.
- a statement of how many times the Cape.....
 definitions of statistical methods and measures:

 the such as t-test (please specify w
- common tests, such as t-test (please specify whether paired vs. unpaired), simple $\chi 2$ tests, Wilcoxon and Mann-Whitney tests, can be unambiguously identified by name only, but more complex techniques should be described in the methods section;
- are tests one-sided or two-sided?
- are there adjustments for multiple comparisons? exact statistical test results, e.g., P values = x but not P values < x;
- definition of 'center values' as median or average
- · definition of error bars as s.d. or s.e.m

Any descriptions too long for the figure legend should be included in the methods section and/or with the source data

n the pink boxes below, please ensure that the answers to the following questions are reported in the manuscript itse every question should be answered. If the question is not relevant to your research, please write NA (non applicable). We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and h

1.a. How was the sample size chosen to ensure adequate power to detect a pre-specified effect size?

Is the variance similar between the groups that are being statistically compared?

USEFUL LINKS FOR COMPLETING THIS FORM

http://www.antibodypedia.com

http://1degreebio.org

http://www.equator-network.org/reporting-guidelines/improving-bioscience-research-reporting-guidelines/improving-bioscience-research-reporting-guidelines/improving-bioscience-research-reporting-guidelines/improving-bioscience-research-reporting-guidelines/improving-bioscience-research-reporting-guidelines/improving-bioscience-research-reporting-guidelines/improving-bioscience-research-reporting-guidelines/improving-bioscience-research-reporting-guidelines/improving-bioscience-research-reporting-guidelines/improving-bioscience-research-reporting-guidelines/improving-bioscience-research-reporting-guidelines/improving-bioscience-research-reporting-guidelines/improving-bioscience-research-reporting-guidelines/improvin

http://grants.nih.gov/grants/olaw/olaw.htm

http://www.mrc.ac.uk/Ourresearch/Ethicsresearchguidance/Useofanimals/index.htm

http://ClinicalTrials.gov

http://www.consort-statement.org

http://www.consort-statement.org/checklists/view/32-consort/66-title

http://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tun

http://datadryad.org

http://figshare.com

http://www.ncbi.nlm.nih.gov/gap

http://www.ebi.ac.uk/ega

http://biomodels.net/

http://biomodels.net/miriam/

http://jij.biochem.sun.ac.za

http://oba.od.nih.gov/biosecurity/biosecurity_documents.html

lease fill out these boxes Ψ (Do not worry if you cannot see all your text once you press retu

http://www.selectagents.gov/

B- Statistics and general methods

stical method was used to predetermine the sample size. The number of samples wer based on the previous experience. We have used atleast three biological replicates pe 1.b. For animal studies, include a statement about sample size estimate even if no statistical methods were used. ot applicable 2. Describe inclusion/exclusion criteria if samples or animals were excluded from the analysis. Were the criteria preot applicable 3. Were any steps taken to minimize the effects of subjective bias when allocating animals/samples to treatment (e.g. ot applicable andomization procedure)? If yes, please describe For animal studies, include a statement about randomization even if no randomization was used. 4.a. Were any steps taken to minimize the effects of subjective bias during group allocation or/and when assessing resultnize the bias between cell types from different age groups, we have included similar age (e.g. blinding of the investigator)? If yes please describe 4.b. For animal studies, include a statement about blinding even if no blinding was done 5. For every figure, are statistical tests justified as appropriate? Do the data meet the assumptions of the tests (e.g., normal distribution)? Describe any methods used to assess it. ne details for the statstical tests used are mentioned in the respective figure legends Is there an estimate of variation within each group of data?

6. To show that antibodies were profiled for use in the system under study (assay and species), provide a citation, catalog	Details are mentioned in the materials and methods.
number and/or clone number, supplementary information or reference to an antibody validation profile. e.g.,	
Antibodypedia (see link list at top right), 1DegreeBio (see link list at top right).	
7. Identify the source of cell lines and report if they were recently authenticated (e.g., by STR profiling) and tested for	Details mentioned in the materials and methods.
mycoplasma contamination.	

D- Animal Models

8. Report species, strain, gender, age of animals and genetic modification status where applicable. Please detail housing	not applicable
and husbandry conditions and the source of animals.	
9. For experiments involving live vertebrates, include a statement of compliance with ethical regulations and identify the	not applicable
committee(s) approving the experiments.	
10. We recommend consulting the ARRIVE guidelines (see link list at top right) (PLoS Biol. 8(6), e1000412, 2010) to ensure	not applicable
that other relevant aspects of animal studies are adequately reported. See author guidelines, under 'Reporting	
Guidelines'. See also: NIH (see link list at top right) and MRC (see link list at top right) recommendations. Please confirm	
compliance.	

E- Human Subjects

11. Identify the committee(s) approving the study protocol.	not applicable
12. Include a statement confirming that informed consent was obtained from all subjects and that the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.	not applicable
13. For publication of patient photos, include a statement confirming that consent to publish was obtained.	not applicable
14. Report any restrictions on the availability (and/or on the use) of human data or samples.	not applicable
15. Report the clinical trial registration number (at ClinicalTrials.gov or equivalent), where applicable.	not applicable
16. For phase II and III randomized controlled trials, please refer to the CONSORT flow diagram (see link list at top right) and submit the CONSORT checklist (see link list at top right) with your submission. See author guidelines, under 'Reporting Guidelines'. Please confirm you have submitted this list.	not applicable
17. For tumor marker prognostic studies, we recommend that you follow the REMARK reporting guidelines (see link list at top right). See author guidelines, under 'Reporting Guidelines'. Please confirm you have followed these guidelines.	not applicable

F- Data Accessibility

generated in this study and deposited in a public database (e.g. RNA-Seq data: Gene Expression Omnibus GSE39462, Proteomics data: PRIDE PXD000208 etc.) Please refer to our author guidelines for 'Data Deposition'. Data deposition in a public repository is mandatory for: a. Protein, DNA and RNA sequences b. Macromolecular structures c. Crystallographic data for small molecules d. Functional genomics data e. Proteomics and molecular interactions 19. Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View or in unstructured repositories such as Dryad (see link list at top right) or Figshare (see link list at top right). 20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	18: Provide a "Data Availability" section at the end of the Materials & Methods, listing the accession codes for data	Provided in the Materials and methods section
Data deposition in a public repository is mandatory for: a. Protein, DNA and RNA sequences b. Macromolecular structures c. Crystallographic data for small molecules d. Functional genomics data e. Proteomics and molecular interactions 19. Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the journal's data policy. If no structured public repositories such structured public repositories value for any datasets in the manuscript as a Supplementary Document (see author guidelines under "Expanded View" or in unstructured repositories such as Dryad (see link list at tor pight) or figshare (see link list at tor pight). 20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	generated in this study and deposited in a public database (e.g. RNA-Seq data: Gene Expression Omnibus GSE39462,	
a. Protein, DNA and RNA sequences b. Macromolecular structures c. Crystallographic data for small molecules d. Functional genomics data e. Proteomics and molecular interactions 19. Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View' or in unstructured repositories such as Dryad (see link list at top right) or Figshare (see link list at top right). 20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	Proteomics data: PRIDE PXD000208 etc.) Please refer to our author guidelines for 'Data Deposition'.	
a. Protein, DNA and RNA sequences b. Macromolecular structures c. Crystallographic data for small molecules d. Functional genomics data e. Proteomics and molecular interactions 19. Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View' or in unstructured repositories such as Dryad (see link list at top right) or Figshare (see link list at top right). 20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-		
b. Macromolecular structures c. Crystallographic data for small molecules d. Functional genomics data e. Proteomics and molecular interactions 9. Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View' or in unstructured repositories such as Dryad (see link list at tor pight) or Figshare (see link list at tor pight). 20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	Data deposition in a public repository is mandatory for:	
c. Crystallographic data for small molecules d. Functional genomics data e. Proteomics and molecular interactions 19. Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of datasets in the manuscript as a Supplementary Document (see author guidelines under "Expanded View" or in unstructured repositories such as Dryad (see link list at top right) or Figshare (see link list at top right). 20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	a. Protein, DNA and RNA sequences	
d. Functional genomics data e. Proteomics and molecular interactions 19. Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View' or in unstructured repositories such as Dryad (see link list at top right) or Figshare (see link list at top right) and the study of the provision of datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	b. Macromolecular structures	
e. Proteomics and molecular interactions 19. Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View' or in unstructured repositories such as Dryad (see link list at top right) or Figshare (see link list at top right). 20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	c. Crystallographic data for small molecules	
19. Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View' or in unstructured repositories such as Dryad (see link list at top right) or Figshare (see link list at top right). 20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	d. Functional genomics data	
journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View' or in unstructured repositories such as Dryad (see link list at top right) or Figshare (see link list at top right). 20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	e. Proteomics and molecular interactions	
datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View' or in unstructured repositories such as Dryad (see link list at top right) or Figshare (see link list at top right). 20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	19. Deposition is strongly recommended for any datasets that are central and integral to the study; please consider the	Data deposited as per journal's policy.
unstructured repositories such as Dryad (see link list at top right) or Figshare (see link list at top right). 20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	journal's data policy. If no structured public repository exists for a given data type, we encourage the provision of	
20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	datasets in the manuscript as a Supplementary Document (see author guidelines under 'Expanded View' or in	
respecting ethical obligations to the patients and relevant medical and legal issues. If practically possible and compatible with the individual consent agreement used in the study, such data should be deposited in one of the major public access-		
with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	20. Access to human clinical and genomic datasets should be provided with as few restrictions as possible while	not applicable
	with the individual consent agreement used in the study, such data should be deposited in one of the major public access-	-
controlled repositories such as dbGAP (see link list at top right) or EGA (see link list at top right).	controlled repositories such as dbGAP (see link list at top right) or EGA (see link list at top right).	
21. Computational models that are central and integral to a study should be shared without restrictions and provided in a not applicable		not applicable
machine-readable form. The relevant accession numbers or links should be provided. When possible, standardized	machine-readable form. The relevant accession numbers or links should be provided. When possible, standardized	
format (SBML, CellML) should be used instead of scripts (e.g. MATLAB). Authors are strongly encouraged to follow the	format (SBML, CellML) should be used instead of scripts (e.g. MATLAB). Authors are strongly encouraged to follow the	
MIRIAM guidelines (see link list at top right) and deposit their model in a public database such as Biomodels (see link list	MIRIAM guidelines (see link list at top right) and deposit their model in a public database such as Biomodels (see link list	
at top right) or JWS Online (see link list at top right). If computer source code is provided with the paper, it should be	at top right) or JWS Online (see link list at top right). If computer source code is provided with the paper, it should be	
deposited in a public repository or included in supplementary information.	deposited in a public repository or included in supplementary information.	

G- Dual use research of concern

22. Could your study fall under dual use research restrictions? Please check biosecurity documents (see link list at top	not applicable
right) and list of select agents and toxins (APHIS/CDC) (see link list at top right). According to our biosecurity guidelines,	
provide a statement only if it could.	

^{*} for all hyperlinks, please see the table at the top right of the document